Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20866202 | 0.95 | SRC (0.46) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL15365341 | 0.95 | AR (0.45) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL15364623 | 0.95 | AR (0.45) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL15365210 | 0.95 | AR (0.45) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL5652331 | 0.95 | SRC (0.46) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL23914846 | 0.86 | AR (0.45) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL5550863 | 0.82 | AR (0.50) | AREGFRERBB2SRCALDH1A1 | |
| SCHEMBL22072959 | 0.81 | PLAU (0.40) | ALDH1A1KDM4EUSP2 | |
| SCHEMBL17341734 | 0.81 | AR (0.46) | ARSRCALDH1A1KDM4EUSP2 | |
| SCHEMBL2164383 | 0.81 | AR (0.46) | ARSRCALDH1A1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411373-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LAB LTD (IN) | 2015-10-21 | — | — | EP | claimed |
| CN-102438995-B | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof | RANBAXY LAB LTD | 2014-12-17 | — | — | CN | claimed |
| US-8440823-B2 | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof | RANBAXY LABORATORIES LIMITED (IN) | 2013-05-14 | — | — | US | claimed |
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2012-04-26 | — | — | US | claimed |
| EP-2411373-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Ranbaxy Laboratories Limited (IN) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109443-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-30 | — | — | WO | claimed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | claimed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | claimed |
| WO-2023107863-A1 | HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | SHIVALIK RASAYAN LIMITED (IN) | 2022-07-28 | — | — | US | disclosed |
| US-10584093-B2 | Method and catalyst for preparing aniline compounds and use thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2020-03-10 | — | — | US | disclosed |
| US-20190100486-A1 | METHOD AND CATALYST FOR PREPARING ANILINE COMPOUNDS AND USE THEREOF | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3015460-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | CERBIOS-PHARMA S A (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-3015460-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | CERBIOS-PHARMA S A (CH) | 2017-05-17 | — | — | EP | disclosed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRAS, EGFR, CSNK1E | AR 3748/4885EGFR 2/4885ERBB2 26/4885 |
| US-20190100486-A1 | METHOD AND CATALYST FOR PREPARING ANILINE COMPOUNDS AND USE THEREOF | CYP3A5, NOX5, NOS2 | AR 1347/4885EGFR 3995/4885ERBB2 3365/4885 |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | EGFR, KRAS, ERBB4 | AR 4488/4885EGFR 1/4885ERBB2 4/4885 |
| US-10584093-B2 | Method and catalyst for preparing aniline compounds and use thereof | CYP3A5, NOX5, NOS2 | AR 1347/4885EGFR 3995/4885ERBB2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.